FXI

WonderFi Announces Expansion into Australia

Retrieved on: 
Tuesday, March 19, 2024
Bitcoin, Ethereum, Deutsche Bank, FXI, Coinsquare, Head, TSX, OTC, HSBC, Clyde & Co, Transaction, Cryptocurrency

FXI is registered in Australia to offer crypto trading and payment remittances within the region.

Key Points: 
  • FXI is registered in Australia to offer crypto trading and payment remittances within the region.
  • WonderFi, through FXI, will launch over-the-counter (OTC) trading services in Australia in Q2 2024, with plans to roll out a comprehensive suite of offerings for retail and institutional traders in Q3 2024.
  • Tim Lo, recently appointed as Head of Sales in the Asia-Pacific (APAC) region, will spearhead the go-to-market strategy in Australia.
  • With its high cryptocurrency adoption rates and vibrant digital asset community, the Australian market has tremendous potential for WonderFi.

FX1 Becomes The New King of Crypto Entertainment

Retrieved on: 
Monday, March 11, 2024
Apple, MMA, Television, Android TV, Combat sport, FX1, FXI, AI, Sport, Cryptocurrency

San Diego, CA, March 11, 2024 (GLOBE NEWSWIRE) -- In a remarkable display of entrepreneurial bravery, the startup FX1 emerged victorious in the high-stakes arena of cryptocurrency entertainment.

Key Points: 
  • San Diego, CA, March 11, 2024 (GLOBE NEWSWIRE) -- In a remarkable display of entrepreneurial bravery, the startup FX1 emerged victorious in the high-stakes arena of cryptocurrency entertainment.
  • Amidst fierce competition and nail-biting suspense, founders Damien Dau and Trent Allan of FX1, a pioneering venture intersecting AI, crypto, and sports entertainment, captivated the judges with their vision and energy.
  • In the wake of their victory, all eyes are now on FX1 as they embark on their journey to reshape the future of sports entertainment , including their intended move into the world of sports betting.
  • It is recommended that you practice due diligence (including consultation with a professional financial advisor) before investing or trading securities and cryptocurrency.

Steel Jupiter's Indoor Air Innovation Receives EPA Device Determination

Retrieved on: 
Tuesday, February 20, 2024
Engineering, RSV, Natural Resources, Fluor Corporation, Chemistry, Research, Lockheed Martin, Filter (signal processing), Patent, Exhalation, FXI, Jupiter, Stanford University, Rice, MRO, Physics, University, School, Respiratory syncytial virus, Virus, Harvard Kennedy School, EPA, Air filter, Medicine, Swansea University, SARS-CoV-2, Steel, Publication, Biology, ESRI, Public

BETHLEHEM, Pa., Feb. 20, 2024 /PRNewswire/ -- Steel Jupiter has achieved a major development milestone with the recent issuance of a device determination from the U.S. Environmental Protection Agency (EPA) for the company's unique and innovative "Zinnia Technology-Coated MERV 8 Air Filter." The EPA's determination confirms that the Zinnia-coated filter operates through dual-action aerosol trapping mechanisms under the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA).

Key Points: 
  • BETHLEHEM, Pa., Feb. 20, 2024 /PRNewswire/ -- Steel Jupiter has achieved a major development milestone with the recent issuance of a device determination from the U.S. Environmental Protection Agency (EPA) for the company's unique and innovative "Zinnia Technology-Coated MERV 8 Air Filter."
  • The EPA's determination confirms that the Zinnia-coated filter operates through dual-action aerosol trapping mechanisms under the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA).
  • With the regulatory path now established, Steel Jupiter can proceed with its go-to-market plan, which includes performance testing multiple filter types across various real-world operational and environmental factors in simulated and actual settings, working with leading indoor air experts.
  • Steel Jupiter anticipates completing this final validation testing over the next several months.

Sirius Therapeutics Begins Phase 1 Clinical Trial of Next-Generation, Long-Acting Factor XI siRNA Anticoagulant for Treatment of Thromboembolic Disorders

Retrieved on: 
Friday, February 2, 2024
Biotechnology, Health, Clinical Trials, Cardiology, Therapy, Pharmacokinetics, FXI, IND, Small RNA, Dyslipidemia, Sirius, Pharmaceutical industry

Sirius Therapeutics, announced it has dosed the first subject in a Phase 1, first-in-human clinical trial in Australia of SRSD107 on January 30th 2024, its next generation siRNA therapeutic targeting coagulation Factor XI (FXI), for the prevention and treatment of thromboembolic disorders.

Key Points: 
  • Sirius Therapeutics, announced it has dosed the first subject in a Phase 1, first-in-human clinical trial in Australia of SRSD107 on January 30th 2024, its next generation siRNA therapeutic targeting coagulation Factor XI (FXI), for the prevention and treatment of thromboembolic disorders.
  • SRSD107 is the second clinical candidate in the company’s portfolio of next generation siRNA therapeutics to treat cardiovascular diseases.
  • The company recently began clinical trials of SRSD101 in China for the treatment of dyslipidemia following IND clearance from the China National Medical Products Administration.
  • “This trial is based on in vivo studies that demonstrated a nearly 100% reduction of FXI levels for up to 6 months, without bleeding events, after a single subcutaneous dose,” said Dr. Qunsheng Ji, Sirius Therapeutics’ Chief Executive Officer.

Former CEO of S&P Dow Jones Indices Alexander J. Matturri, Jr. Joins SOFR Academy

Retrieved on: 
Monday, January 22, 2024
Professional Services, Education, Business, Data Analytics, Finance, Other Education, Senior, DWS Group, CBOE, Lehigh University, Area studies, AXI, CFA, Invesco, FXI, Senior advisor, Index, S&P Dow Jones Indices, Advisory board, S&P, Cboe Global Markets, Syracuse University, Risk management

Mr. Matturri was previously Chief Executive Officer of S&P Dow Jones Indices (“S&P DJI”), a position he held from 2007 until retiring in 2020.

Key Points: 
  • Mr. Matturri was previously Chief Executive Officer of S&P Dow Jones Indices (“S&P DJI”), a position he held from 2007 until retiring in 2020.
  • “I am happy to be able to help SOFR Academy as it helps educate and develop products for the credit markets.
  • “Under Alex’s leadership, S&P Dow Jones Indices was transformed into one of the world’s most important index providers.
  • These indices work in conjunction with the SOFR and address a concern communicated by a group of American banks.

OneSpan Introduces New Partner Network Program to Broaden Delivery of Secure and Seamless Customer Experiences

Retrieved on: 
Wednesday, December 6, 2023
Software, Hardware, Artificial Intelligence, Professional Services, Technology, Fintech, Online Privacy, Security, OneSpan, DNA, Organization, FXI, Workforce, Public company, Region, FIDO, Marketing, Documentation, FedRAMP, Partnership, Growth, Knowledge, Certification, Online shopping, Video game, Renewable energy, Nuvia Mayorga Delgado

OneSpan ™ (NASDAQ: OSPN), the digital agreements security company, today announced the launch of a new partner network program that now provides a comprehensive set of benefits that will drive growth and help OneSpan partners deliver seamless and secure customer experiences.

Key Points: 
  • OneSpan ™ (NASDAQ: OSPN), the digital agreements security company, today announced the launch of a new partner network program that now provides a comprehensive set of benefits that will drive growth and help OneSpan partners deliver seamless and secure customer experiences.
  • Whether it's for workforce authentication or to secure digital workflows, OneSpan offers enterprise-grade solutions that provide continuous identity verification and authentication, e-signature, high-assurance virtual collaboration, and secure storage.
  • “Our partners play a critical role in delivering trust to organizations and end users throughout the entire customer journey.
  • The OneSpan Partner Network represents a significant milestone in delivering on our promise to help our customers and partners secure their customer-facing and revenue-generating processes.”
    The OneSpan Partner Network meets the needs of the company’s growing partner ecosystem, with a special focus on an accelerated onboarding process.

Sirius Therapeutics Announces Submission to Begin First Clinical Trial of Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders

Retrieved on: 
Friday, November 10, 2023
Cardiology, Biotechnology, Other Health, Health, General Health, Pharmaceutical, Other Science, Research, Genetics, Science, Clinical Trials, Medicine, Sirius, Clinical trial, Pharmacology, Patient, Therapy, FXI, Pharmaceutical industry

Sirius Therapeutics today announced it has submitted an application in Australia to begin a first-in-human clinical trial of SRSD107, its next generation siRNA therapeutic for the prevention and treatment of thromboembolic disorders.

Key Points: 
  • Sirius Therapeutics today announced it has submitted an application in Australia to begin a first-in-human clinical trial of SRSD107, its next generation siRNA therapeutic for the prevention and treatment of thromboembolic disorders.
  • SRSD107, which specifically targeting coagulation factor XI (FXI), is the first Sirius-developed compound to reach clinical stage of development globally.
  • “We have made rapid progress in developing SRSD107 and other candidates in our pipeline since Sirius was established two years ago.
  • This submission marks our transition from discovery to clinical stage development,” said Dr. Qunsheng Ji, Sirius Therapeutics Chief Executive Officer.

SOFR Academy Welcomes Publication of Japanese AXI and FXI Feasibility Study in connection with Reference Rate Reform

Retrieved on: 
Tuesday, September 12, 2023
Banking, Other Professional Services, Professional Services, Finance, Faculty, FXI, Feedback, SOFR, Keio University, University of Kragujevac Faculty of Economics, Index, AXI, Invesco, Mizuho Securities USA, Business administration, Seikei University, NYSE, Pharmaceutical industry, Bank, Economics

The paper is a feasibility study of a Japanese version of Across-the-Curve Credit Spread Index (JPAXI) and the Financial Condition Credit Spread Index (JPFXI) accounting for specific features of the Japanese corporate bond market.

Key Points: 
  • The paper is a feasibility study of a Japanese version of Across-the-Curve Credit Spread Index (JPAXI) and the Financial Condition Credit Spread Index (JPFXI) accounting for specific features of the Japanese corporate bond market.
  • I am very grateful to Professors Okimoto and Takaoka.”
    The Japanese AXI and FXI feasibility study is available for download here and market participants can learn more about Japanese FXI and view related resources here .
  • These indices work in conjunction with the Secured Overnight Financing Rate (“SOFR”) and address concerns communicated by a group of American banks.
  • The publication of the Japanese feasibility study complements studies for China and Europe .

FXI Announces Expiration and Final Results of Previously Announced Exchange Offer and Consent Solicitation for its 7.875% Senior Secured Notes due 2024

Retrieved on: 
Monday, May 1, 2023
FXI, Solicitation, Communication, Chicago Telephone Company Kedzie Exchange, Consent, Senior, Settlement date, SEC Rule 144A, Initial exchange offering, Expiration date, Exchange, Eligibility, Latham & Watkins, Person, Sale, Amendment, Date, Expiration, The Company, Jefferies Group, Convention to propose amendments to the United States Constitution, Security (finance), Letter, Exchange offer, Regulation, Note

The Exchange Offer and Consent Solicitation expired at 11:59 p.m., New York City time, on April 28, 2023 (the "Expiration Date").

Key Points: 
  • The Exchange Offer and Consent Solicitation expired at 11:59 p.m., New York City time, on April 28, 2023 (the "Expiration Date").
  • As of the Expiration Date, all conditions to the Exchange Offer and Consent Solicitation were satisfied or waived.
  • Jefferies LLC is acting as dealer manager and solicitation agent in connection with the Exchange Offer and Consent Solicitation.
  • Latham & Watkins LLP is acting as legal counsel to the Company in connection with the Exchange Offer and Consent Solicitation.

Designing Spaces of Hope: Liam's Story, Surprises Family of Special Needs Child

Retrieved on: 
Wednesday, March 15, 2023
Genetic disorder, Water, Stomach, Syndrome, Partnership, Seizure, FXI, Male, Patient, Lake Worth, Child, Intellectual disability, GE Appliances, Volunteering, Family, Spaces, Hope

LAKE WORTH, Fla., March 15, 2023 /PRNewswire/ -- Designing Spaces brings hope and help to a Lake Worth Child who suffers from Allan-Herndon-Dudley Syndrome on Designing Spaces of Hope: Liam's Story.

Key Points: 
  • LAKE WORTH, Fla., March 15, 2023 /PRNewswire/ -- Designing Spaces brings hope and help to a Lake Worth Child who suffers from Allan-Herndon-Dudley Syndrome on Designing Spaces of Hope: Liam's Story.
  • This special airs on May 12 and May 18, at 7:30 a.m. on Lifetime.
  • There are only 300 cases worldwide with only 3 to 4 cases in the United States, affecting all male patients, including Liam.
  • "I'm so thankful to Designing Spaces for gifting us items that will make life easier in the home and outside the home, for not only myself, but for Liam," says Bolufé.